

**QUALIFICATION CERTIFICATE
PURSUANT TO NATIONAL INSTRUMENT 44-101
AND NATIONAL INSTRUMENT 44-102**

January 14, 2022

British Columbia Securities Commission (Principal Regulator)
Ontario Securities Commission
Alberta Securities Commission
Autorité des marchés financiers
Financial and Consumer Affairs Authority of Saskatchewan
Manitoba Securities Commission
Financial and Consumer Services Commission of New Brunswick
Nova Scotia Securities Commission
Office of the Superintendent of Securities, Prince Edward Island
Office of the Superintendent of Securities, Newfoundland and Labrador
Office of the Yukon Superintendent of Securities
Office of the Superintendent of Securities, Northwest Territories
Nunavut Securities Office

**Re: Entheon Biomedical Corp.
 Preliminary Short Form Base Shelf Prospectus dated January 14, 2022
 (the "Preliminary Prospectus")**

The undersigned, being one of the executive officers of Entheon Biomedical Corp. (the "**Company**"), hereby certifies on behalf of the Company, pursuant to section 4.1(a)(ii) of National Instrument 44-101 *Short Form Prospectus Distributions* ("**NI 44-101**"), that as at the date of this certificate:

- (i) the Company is relying on section 2.2 of NI 44-101 in order to be qualified to file a prospectus in the form of a short form prospectus;
- (ii) all of the qualification criteria set forth in section 2.2 of NI 44-101 have been satisfied; and
- (iii) all of the material incorporated by reference in the preliminary short form prospectus and not previously filed is being filed with the preliminary short form prospectus.

ENTHEON BIOMEDICAL CORP

"Timothy Ko"

Timothy Ko
Chief Executive Officer, President and Director